Regeneron Pharmaceuticals (REGN) Income from Continuing Operations (2009 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly Income from Continuing Operations of 1296900000.0 for Q2 2026, down 6.81% year-over-year from 1391600000.0 in Q2 2025, and up 78.34% quarter-over-quarter from 727200000.0 in Q1 2026.
Regeneron Pharmaceuticals (REGN) Income from Continuing Operations (2009 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' Income from Continuing Operations history runs 18 years deep, the most recent figure standing at 1296900000.0 for Q2 2026.
- In Q2 2026, Income from Continuing Operations fell 6.81% year-over-year to 1296900000.0; the TTM figure through Jun 2026 stood at 4328700000.0 (down 2.91% YoY), while the FY2025 annual figure was 4504900000.0, up 2.09% from the prior year.
- Income from Continuing Operations for Q2 2026 stood at 1296900000.0, up from 727200000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 1460000000.0 in Q3 2025, with the low at 722000000.0 in Q1 2024.
- The 5-year median for Income from Continuing Operations is 990650000.0 (2022), against an average of 1068533333.33.
- The sharpest annual moves came in 2022 and 2024: Income from Continuing Operations sank 72.5% in 2022, then surged 47.9% in 2024.
- Regeneron Pharmaceuticals' Income from Continuing Operations stood at 1197100000.0 in 2022, then fell by 3.13% to 1159600000.0 in 2023, then retreated by 20.86% to 917700000.0 in 2024, then slipped by 7.97% to 844600000.0 in 2025, then surged by 53.55% to 1296900000.0 in 2026.
- Business Quant data shows REGN's Income from Continuing Operations at 1296900000.0 in Q2 2026, 727200000.0 in Q1 2026, and 844600000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -290.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.30 Bn |
| Mar 31, 2026 | 727.20 Mn |
| Dec 31, 2025 | 844.60 Mn |
| Sep 30, 2025 | 1.46 Bn |
| Jun 30, 2025 | 1.39 Bn |
| Mar 31, 2025 | 808.70 Mn |
| Dec 31, 2024 | 917.70 Mn |
| Sep 30, 2024 | 1.34 Bn |
| Jun 30, 2024 | 1.43 Bn |
| Mar 31, 2024 | 722.00 Mn |
| Dec 31, 2023 | 1.16 Bn |
| Sep 30, 2023 | 1.01 Bn |
| Jun 30, 2023 | 968.40 Mn |
| Mar 31, 2023 | 817.80 Mn |
| Dec 31, 2022 | 1.20 Bn |
| Sep 30, 2022 | 1.32 Bn |
| Jun 30, 2022 | 852.10 Mn |
| Mar 31, 2022 | 973.50 Mn |
| Dec 31, 2021 | 2.23 Bn |
| Sep 30, 2021 | 1.63 Bn |